FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175533935> ?p ?o ?g. }

• W3175533935 abstract "Introduction: Primary diffuse large B-cell lymphoma of the testis (PTL) represents a unique condition characterized by high long-term risk of contralateral testis and central nervous system (CNS) relapse (>30% at 15 years) in historical series (Zucca et al, JCO 2002). Immunochemotherapy associated with intrathecal CNS prophylaxis and contralateral testis radiotherapy (RT) improved patient outcome, with a virtual elimination of contralateral recurrences and significant reduction (6% at 5 years) of CNS relapses in the IELSG10 trial (Vitolo et al., JCO 2011). The International Extranodal Lymphoma Study Group (IELSG), in cooperation with the Italian Lymphoma Foundation (FIL), coordinated the multicenter phase II IELSG30 study to assess activity and feasibility of intensified CNS prophylaxis in combination with chemoimmunotherapy and RT. Patients and Methods: Patients with stage I-II PTL were eligible. Treatment consisted of 6 cycles of the standard R-CHOP21 regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone every 21 days); 4 doses of intrathecal liposomal cytarabine; 2 courses of intravenous (iv) intermediate-dose methotrexate (1.5 gr/m2) and RT (25-30 Gy) to the contralateral testis. The study was designed to demonstrate (80% power, a = .05) a PFS improvement from 67% to 82% at 10 years (primary endpoint). Results: Fifty-four patients (median age: 66 years, range: 37-79 years) with untreated stage I (n = 32) or II (n = 22) PTL were treated with R-CHOP21, 53 received at least 3 doses of intrathecal CNS prophylaxis, 48 received at least one dose of iv methotrexate and 50 received prophylactic RT. No unexpected side effects were observed. At a median follow-up of 5 years, 7 patients progressed and 7 died, with 5-year PFS of 88% (95%CI, 74-94%) and 5-year OS of 92% (95%CI, 79%-97%). No CNS relapses occurred. In 4 cases, both nodal and extranodal relapses were reported, the latter including the gastrointestinal tract and the pleurae in the same patient, as well as, 1 patient each, the kidneys, the spinal canal (extra-axial) and the contralateral testis (9 years after RT). Two patients relapsed only at extranodal sites (skin, adrenal gland), 1 had nodal relapse. Notably, 4 of 7 failures were late relapses occurring after 6 to 10 years from treatment. Causes of death were lymphoma (n = 4), second cancer (n = 1), cerebral vasculopathy (n = 1), unknown (n = 1). The research was funded by: Mundipharma provided the drug depocyte free of charge Keywords: Combination Therapies, Radiation Therapy Conflicts of interests pertinent to the abstract A. J. M. Ferreri Consultant or advisory role: Adienne - Gilead - Novartis - Juno - PletixaPharm Research funding: BMS - Beigene - Pharmacyclics - Hutchison - Medipharma - Amgen - Genmab - ADC - Therapeutics - Gilead - Novartis - Pfizer E. Zucca Consultant or advisory role: Beigene - Celgene - Incyte - Janssen - Merck - Roche - Celltrion Healthcare - Kite (Gilead) Research funding: AstraZeneca - Celgene - Incyte - Janssen - Merck - Roche Educational grants: Roche – Abbvie" @default.
• W3175533935 created "2021-07-05" @default.
• W3175533935 creator A5000403848 @default.
• W3175533935 creator A5007978440 @default.
• W3175533935 creator A5009234092 @default.
• W3175533935 creator A5017472528 @default.
• W3175533935 creator A5024161871 @default.
• W3175533935 creator A5036693524 @default.
• W3175533935 creator A5041745367 @default.
• W3175533935 creator A5054623894 @default.
• W3175533935 creator A5058703562 @default.
• W3175533935 creator A5063805789 @default.
• W3175533935 creator A5070003191 @default.
• W3175533935 creator A5075117420 @default.
• W3175533935 creator A5076236981 @default.
• W3175533935 creator A5084154600 @default.
• W3175533935 creator A5085410438 @default.
• W3175533935 creator A5088571057 @default.
• W3175533935 date "2021-06-01" @default.
• W3175533935 modified "2023-10-13" @default.
• W3175533935 title "INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL" @default.
• W3175533935 doi "https://doi.org/10.1002/hon.48_2879" @default.
• W3175533935 hasPublicationYear "2021" @default.
• W3175533935 type Work @default.
• W3175533935 sameAs 3175533935 @default.
• W3175533935 citedByCount "13" @default.
• W3175533935 countsByYear W31755339352022 @default.
• W3175533935 countsByYear W31755339352023 @default.
• W3175533935 crossrefType "journal-article" @default.
• W3175533935 hasAuthorship W3175533935A5000403848 @default.
• W3175533935 hasAuthorship W3175533935A5007978440 @default.
• W3175533935 hasAuthorship W3175533935A5009234092 @default.
• W3175533935 hasAuthorship W3175533935A5017472528 @default.
• W3175533935 hasAuthorship W3175533935A5024161871 @default.
• W3175533935 hasAuthorship W3175533935A5036693524 @default.
• W3175533935 hasAuthorship W3175533935A5041745367 @default.
• W3175533935 hasAuthorship W3175533935A5054623894 @default.
• W3175533935 hasAuthorship W3175533935A5058703562 @default.
• W3175533935 hasAuthorship W3175533935A5063805789 @default.
• W3175533935 hasAuthorship W3175533935A5070003191 @default.
• W3175533935 hasAuthorship W3175533935A5075117420 @default.
• W3175533935 hasAuthorship W3175533935A5076236981 @default.
• W3175533935 hasAuthorship W3175533935A5084154600 @default.
• W3175533935 hasAuthorship W3175533935A5085410438 @default.
• W3175533935 hasAuthorship W3175533935A5088571057 @default.
• W3175533935 hasConcept C126322002 @default.
• W3175533935 hasConcept C126894567 @default.
• W3175533935 hasConcept C141071460 @default.
• W3175533935 hasConcept C168563851 @default.
• W3175533935 hasConcept C203092338 @default.
• W3175533935 hasConcept C2776694085 @default.
• W3175533935 hasConcept C2776755627 @default.
• W3175533935 hasConcept C2778041864 @default.
• W3175533935 hasConcept C2778720950 @default.
• W3175533935 hasConcept C2779338263 @default.
• W3175533935 hasConcept C2779429289 @default.
• W3175533935 hasConcept C2780653079 @default.
• W3175533935 hasConcept C2780790343 @default.
• W3175533935 hasConcept C2781059491 @default.
• W3175533935 hasConcept C2781413609 @default.
• W3175533935 hasConcept C71924100 @default.
• W3175533935 hasConcept C90924648 @default.
• W3175533935 hasConceptScore W3175533935C126322002 @default.
• W3175533935 hasConceptScore W3175533935C126894567 @default.
• W3175533935 hasConceptScore W3175533935C141071460 @default.
• W3175533935 hasConceptScore W3175533935C168563851 @default.
• W3175533935 hasConceptScore W3175533935C203092338 @default.
• W3175533935 hasConceptScore W3175533935C2776694085 @default.
• W3175533935 hasConceptScore W3175533935C2776755627 @default.
• W3175533935 hasConceptScore W3175533935C2778041864 @default.
• W3175533935 hasConceptScore W3175533935C2778720950 @default.
• W3175533935 hasConceptScore W3175533935C2779338263 @default.
• W3175533935 hasConceptScore W3175533935C2779429289 @default.
• W3175533935 hasConceptScore W3175533935C2780653079 @default.
• W3175533935 hasConceptScore W3175533935C2780790343 @default.
• W3175533935 hasConceptScore W3175533935C2781059491 @default.
• W3175533935 hasConceptScore W3175533935C2781413609 @default.
• W3175533935 hasConceptScore W3175533935C71924100 @default.
• W3175533935 hasConceptScore W3175533935C90924648 @default.
• W3175533935 hasIssue "S2" @default.
• W3175533935 hasLocation W31755339351 @default.
• W3175533935 hasOpenAccess W3175533935 @default.
• W3175533935 hasPrimaryLocation W31755339351 @default.
• W3175533935 hasRelatedWork W1896861650 @default.
• W3175533935 hasRelatedWork W1921119956 @default.
• W3175533935 hasRelatedWork W1986487042 @default.
• W3175533935 hasRelatedWork W1996462672 @default.
• W3175533935 hasRelatedWork W2017046780 @default.
• W3175533935 hasRelatedWork W2031021461 @default.
• W3175533935 hasRelatedWork W2044362603 @default.
• W3175533935 hasRelatedWork W2047206303 @default.
• W3175533935 hasRelatedWork W2138201596 @default.
• W3175533935 hasRelatedWork W2143831053 @default.
• W3175533935 hasVolume "39" @default.
• W3175533935 isParatext "false" @default.
• W3175533935 isRetracted "false" @default.
• W3175533935 magId "3175533935" @default.
• W3175533935 workType "article" @default.